Immunotherapy - Checkpoint Inhibitor, Targeted Immunotherapy Drugs
Offered By: Mary Greeley Medical Center via YouTube
Course Description
Overview
Syllabus
Intro
Case Presentation
Immune Checkpoints --Biology
PD1 Inhibitor for Melanoma
PD1 Trials in Melanoma
Combination of CTLA4 and PD1 blockade in Melanoma: Checkmate 067 Trial
Adjuvant Checkpoint Inhibitor Treatment --Melanoma Adjuvant Ipilimumab was studied in comparison to placebo in treatment of patients who had undergone complete resection of stage lIl Melanoma at a dose of 10 mg.kg every 3 weeks X 4 followed by every 3 months X 3 years. - At 5.3 years follow-up the recurrence free survival was 40.8% in Ipilimumab group compared to 30.3% in placebo
Adjuvant PD1 Inhibitors for Stage III Melanoma
Checkpoint Inhibitors in Advanced NSCLC
Predictors of Response
(PACIFIC Trial) Checkpoint Inhibitor as Adjuvant Therapy after Chemo- Radiotherapy for Stage III NSCLC
Management of Toxicity
Taught by
Mary Greeley Medical Center
Related Courses
Demystifying Targeted Cancer TreatmentsCancer Research UK via FutureLearn Viruses and Human Cancers
Institut Pasteur via France Université Numerique Introduction à l'immunologie: méthodes et applications médicales
École Polytechnique Fédérale de Lausanne via edX Foundations of Understanding and Combating Cancer
Cornell University via World Science U Medicine Grand Rounds - Immune-Related Toxicities with Immune Checkpoint Inhibitors
Dartmouth College via Independent